Romosozumab

Study Overview

Brief Summary

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.

The Clinical Study website with more information can be found here

This is a Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta.

You can also find more information here.

See more Research & Studies

See more research & studies

Romosozumab

Exploring the barriers and enablers to accessible and inclusive dental care

The hospital of no surprises

Ultragenyx-led ORBIT Study

Matrix-Directed Therapy in Older Adolescents and Adults with Osteogenesis Imperfecta – The “MOI-A” Study

$Exploring the parent/carer experience of unexplained bone fractures and examinations undertaken in the radiology department prior to formal diagnosis of OI$